Alec Broers becomes chairman of Bio Nano Consulting
Brings extensive industry, academic and scientific expertise to company
Broers has extensive industry, academic and scientific expertise and was chairman of the House of Lords Science and Technology Select Committee between 2004 and 2007.
At Bio Nano Consulting he will facilitate ongoing partnerships between academia and the wider life science and technology industries.
Educated at Melbourne University and the University of Cambridge, Broers subsequently worked in r&d at IBM laboratories in the US for 19 years, ultimately taking responsibility for the company’s chip development.
Broers returned to the UK in 1984 as head of Electrical Engineering at Cambridge University and Fellow of Trinity College. He subsequently became head of the Department of Engineering and Master of Churchill College.
More recently, Broers was Vice Chancellor of Cambridge University and president of the Royal Academy of Engineering from 2001 to 2006. He was knighted in 1998 for services to education before being made a life peer in 2004.
Bio Nano Consulting is a joint venture of Imperial College London and University College London that specialises in solutions to industry across the life sciences and technology sectors.
You may also like
Manufacturing
Nulogy launches Supplier Compliance Management to build stronger, more resilient supplier networks
Nulogy, a leading provider of manufacturing operations software, announced the launch of Nulogy Supplier Compliance Management, a solution designed to centralise and automate supplier compliance for procurement, supply chain, and quality assurance teams in manufacturing, food & beverage, pharmaceuticals, and
other highly regulated industries
Research & Development
COVID-19 immunity lowers the risk of a new pandemic
Researchers at the MRC-University of Glasgow Centre for Virus Research have demonstrated that the likelihood of the emergence of a new SARS-type virus pandemic has been significantly reduced by population-wide immunity to SARS-CoV-2
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
Cytiva enters research partnership with SRTIGET for next-gen genomic medicine
The pair aim to expand the role of lipid nanoparticle technology into gene therapy delivery, including applications in cancer and inherited blood diseases, CNS delivery for neurological disorders where current methods fail and in vivo stem cell modification that could eliminate toxic conditioning regimens